ARTICLE

Year : 2016  |  Volume : 5  |  Issue : 5  |  Page : 62-63

Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience

Alena Skrahina¹, Hennadz Hurevich¹, Dennis Falzon², Liudmila Zhilevich³, Valiantsin Rusovich⁴, Masoud Dara⁵, Svetlana Setkina^6
1 Republican Scientific and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus
² Global Tuberculosis Programme, World Health Organisation, Geneva, Switzerland
³ General Directorate of Medical Care, Ministry of Health, Minsk, Belarus
⁴ Country Office, World Health Organisation, Minsk, Belarus
⁵ Regional Office for Europe, World Health Organisation, Copenhagen, Denmark
⁶ Centre for Examinations and Tests in Health Care, Minsk, Belarus

Correspondence Address:
Alena Skrahina
Republican Scientific and Practical Centre for Pulmonology and Tuberculosis, Minsk
Belarus

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.1016/j.ijmyco.2016.11.014

Background/objective: Outcomes of treatment for multidrug-resistant tuberculosis (MDR-TB) remain poor worldwide. Among patients with MDR-TB in Belarus who started treatment in 2012, only 54% completed it successfully, with treatment failure reported in 22% of the patients; additionally, 11% died and 13% were lost to follow-up or remained unevaluated. In Belarus, to improve outcomes, bedaquiline was introduced in MDR-TB treatment in June 2015. The national TB program developed measures to monitor safety and effectiveness of bedaquiline-containing regimens in line with the World Health Organization recommendations.
Methods: After enrollment of patients, clinical, radiological, laboratory, and microbiological data were carefully collected at start, during treatment, and at follow-up. A total of 197 patients were enrolled: male, 140 (71%); female, 57 (29%); new TB cases, 83 (42%); previously treated, 114 (58%); extensively drug-resistant-TB (XDR-TB), 128 (65%), pre-XDR-TB (fluoroquinolone resistant), 34 (17%), pre-XDR-TB (injectables resistant), 25 (13%), and other MDR-TB cases, 10 (5%).
Results: According to the intermediate analysis, 186 patients currently are continuing with the treatment, two patients died, and nine patients were lost to follow-up. Sputum culture conversion were observed in 186 patients (94%) at 6 months and one (0.5%) of these 197 patients started treatment; six patients (3%) remain sputum culture positive. The safety data were as follows: 135 patients (68%) experienced metabolism and nutrition disorders (hyperuricemia being the most common), 127 patients (64%) experienced hepatobiliary disorders (hepatic functions abnormality being the most common), 93 patients (47%) experienced electrolyte disorders (hypomagnesemia being the most common), 80 patients (41%) experienced cardiac disorders (abnormal electrocardiogram and arrhythmia being the most common), 68 patients (35%) experienced gastrointestinal system disorders (nausea, vomiting, and abdominal pain being the most common disorders), 54 patients (27%) experienced blood and the lymphatic system disorders (low platelet count being the most common), 42 patients (21%) experienced renal and urinary disorders (creatinine clearance decrease being the most common), 40 patients (20%) experienced nervous system disorders (headache, dizziness, and paresthesia being the most common ones), 36 patients (18%) experienced skin and subcutaneous tissue disorders (rush and pruritus being the most common), 35 patients (17%) experienced ear and labyrinth disorders (tinnitus and decreased hearing being the most common ones), 32 patients (15%) experienced psychiatric disorders (insomnia being the most common disorder), and 30 patients (14%) experienced infections and infestations (candidiasis being the most common). The most adverse events were mild or moderate in severity and reversible. One death was possibly related to MDR-TB therapy.
Conclusion: Our interim results on safety and effectiveness of bedaquiline-containing regimens in multidrug and extensively drug-resistant tuberculosis (M/XDR-TB) patients are encouraging. They will add value to understanding role and place of this new anti-TB drug in M/XDR-TB treatment.

Keywords: Anti-TB drug, Bedaquiline, Multidrug and extensively drug-resistant tuberculosis, Multidrug-resistant tuberculosis

Conflicts of interest

This article has been cited by 1 Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician’s perspective Lorenzo Guglielmetti,Sheila Chiesi,Johannes Eimer,Jose Dominguez,Tiziana Masini,Francis Varaine,Nicolas Veziris,Florence Ader,Jérôme Robert Future Microbiology. 2020; [Pubmed] | [DOI] 2 The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa Abela Mpobela Agnarson,Abeda Williams,Chrispin Kambili,Gunnar Mattson,Laurent Metz Expert Review of Anti-infective Therapy. 2020; : 1 [Pubmed] | [DOI] 3 Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China Abela Mpobela Agnarson,Xiao Chun Wang,Ravi Potluri,Hitesh Bhandari,Amit Dhir,Chrispin Kambili,Laurent Metz BMC Infectious Diseases. 2020; 20(1) [Pubmed] | [DOI] 4 Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis Lawrence Mbuagbaw,Lorenzo Guglielmetti,Catherine Hewison,Nyasha Bakare,Mathieu Bastard,Eric Caumes,Mathilde Fréchet-Jachym,Jérôme Robert,Nicolas Veziris,Naira Khachatryan,Tinatin Kotrikadze,Armen Hayrapetyan,Zaza Avaliani,Holger J. Schünemann,Christian Lienhardt Emerging Infectious Diseases. 2019; 25(5) [Pubmed] | [DOI] 5 Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences Edine Tiemersma,Susan van den Hof,Gunta Dravniece,Fraser Wares,Yohannes Molla,Yusie Permata,Endang Lukitosari,Mamel Quelapio,Si Thu Aung,Khay Mar Aung,Hoang Thanh Thuy,Vu Dinh Hoa,Merkinai Sulaimanova,Saadat Sagyndikova,Mavluda Makhmudova,Alijon Soliev,Michael Kimerling European Respiratory Review. 2019; 28(153): 180115 [Pubmed] | [DOI] 6 New drugs and regimens for tuberculosis Kwok-Chiu Chang,Eric Nuermberger,Giovanni Sotgiu,Chi-Chiu Leung Respirology. 2018; [Pubmed] | [DOI] 7 Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging Yang Li,Feng Sun,Wenhong Zhang Drug Development Research. 2018; [Pubmed] | [DOI] 8 Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline Emanuele Pontali,Lia DæAmbrosio,Rosella Centis,Giovanni Sotgiu,Giovanni Battista Migliori European Respiratory Journal. 2017; 49(3): 1700146 [Pubmed] | [DOI] 9 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Ioana D. Olaru,Jan Heyckendorf,Sönke Andres,Barbara Kalsdorf,Christoph Lange European Respiratory Journal. 2017; 49(5): 1700742 [Pubmed] | [DOI] 10 Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis Priya Singh,Rashmi Kumari,Rup Lal Indian Journal of Microbiology. 2017; [Pubmed] | [DOI] 11 Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Lorenzo Guglielmetti European Respiratory Journal. 2017; 49(5): 1700738 [Pubmed] | [DOI] 12 Bedaquiline Reactions Weekly. 2017; 1643(1): 52 [Pubmed] | [DOI]